ReviewDrug discovery today2016
Microfluidic models for adoptive cell-mediated cancer immunotherapies.
Review in Drug discovery today, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Microfluidic technologies for enhancing the potency, predictability and affordability of adoptive cell therapies.Nature biomedical engineering · 2025Review
- Emerging Molecular Technology in Cancer Testing.EJIFCC · 2024Review
- Microphysiological Systems for Cancer Immunotherapy Research and Development.Advanced biology · 2024Review
- Themis controls T cell activation, effector functions, and metabolism of peripheral CD8Life science alliance · 2023Article
- Numerical Modeling of Physical Cell Trapping in Microfluidic Chips.Micromachines · 2023Article
- Characterization of 3D heterocellular spheroids of pancreatic ductal adenocarcinoma for the study of cell interactions in the tumor immune microenvironment.Frontiers in oncology · 2023Article
- Tumor heterogeneity: preclinical models, emerging technologies, and future applications.Frontiers in oncology · 2023Review
- Recent Trends and Opportunities for the Targeted Immuno-Nanomaterials for Cancer Theranostics Applications.Micromachines · 2022Review
- Recent advances for cancer detection and treatment by microfluidic technology, review and update.Biological procedures online · 2022Review
- Tumor Microenvironment and Hydrogel-Based 3D Cancer Models for In Vitro Testing Immunotherapies.Cancers · 2022Review
- Effects of extracellular adhesion molecules on immune cell mediated solid tumor cell killing.Frontiers in immunology · 2022Article
- A Perfusion Model to Evaluate Response to Photodynamic Therapy in 3D Tumors.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Review
- Engineered in vitro tumor models for cell-based immunotherapy.Acta biomaterialia · 2021Review
- The future of microfluidics in immune checkpoint blockade.Cancer gene therapy · 2021Review
- Reconstructing the tumor architecture into organoids.Advanced drug delivery reviews · 2021Review
- Microfluidic technologies for immunotherapy studies on solid tumours.Lab on a chip · 2021Review
- Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
- Microfluidic systems for hydrodynamic trapping of cells and clusters.Biomicrofluidics · 2020Review
- Integrated in silico and 3D in vitro model of macrophage migration in response to physical and chemical factors in the tumor microenvironment.Integrative biology : quantitative biosciences from nano to macro · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Current adoptive T cell therapies have shown promising results in clinical trials but need further development as an effective cancer treatment. Here, we discuss how 3D microfluidic tumour models mimicking the tumour microenvironment could help in testing T cell immunotherapies by assessing engineered T cells and identifying combinatorial therapy to improve therapeutic efficacy. We propose that 3D microfluidic systems can be used to screen different patient-specific treatments, thereby reducing the burden of in vivo testing and facilitating the rapid translation of successful T cell cancer immunotherapies to the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.